The top 100 stock
market authors
selected for publication
market authors
selected for publication
»
Comments
» ADLS
You are currently following David White
Stop FollowingYou are no longer following David White
-
486
)
13 Extreme FDA Trades [View article]
The non-"me to" aspect of it is that it is effective against strains of bacteria that are already resistance to penecillin, macrolide, and fluoroquinolone.
Essentially as antibiotics are used more and more over long periods of time, strains of "hardier" bacteria emerge (mutations)that have developed resistance to the antibiotics. For this reason there is a need to continually produce/invent new atibiotics to which the bacteria are not yet resistant.
Pneumonia is a very common disease. It can be a killer. We need to have drugs that can effectively combat the bacteria that cause it. In that sense, Restanza is not a "me to" drug.